Low Anti-Tumor Necrosis Factor Levels During Maintenance Phase Are Associated With Treatment Failure in Children With Crohn’s Disease
Inflammatory Bowel Diseases · 2025
DOI: 10.1093/ibd/izae239 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Inflammatory Bowel Diseases, 2025. Verfasst von Jonathan Moses und 42 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Stanford Medicine Children's Health, Palo Alto, CA, USA. Hauptthemen laut MEDLINE: Crohn Disease, Adalimumab, Infliximab, Methotrexate. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Patient Centered Outcomes Research Institute, Helmsley Charitable Trust, Progenika Biopharma.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Higher drug levels and combination therapy with low-dose oral methotrexate (LD-MTX) may reduce anti-tumor necrosis factor (TNF) treatment failure in pediatric Crohn’s disease. We sought to (1) evaluate whether combination therapy with LD-MTX was associated with higher anti-TNF levels, (2) evaluate associations between anti-TNF levels and subsequent treatment failure, and (3) explore the effect of combination therapy on maintenance of remission among patients with therapeutic drug levels (>5 µg/mL for infliximab and >7.5 µg/mL for adalimumab).
Methods
We conducted a post hoc analysis of the COMBINE trial, which compared anti-TNF monotherapy to combination therapy with LD-MTX. We included participants who entered maintenance therapy and provided a serum sample approximately 4 months from randomization.
Results
Among 112 infliximab and 41 adalimumab initiators, median drug levels were similar between combination therapy and monotherapy (infliximab: 8.8 vs 7.5 μg/mL [P = .49]; adalimumab: 11.1 vs 10.5 μg/mL [P = .11]). Median drug levels were lower in patients experiencing treatment failure (infliximab: 4.2 vs 9.6 μg/mL [P < .01]; adalimumab: 9.1 vs 12.3 μg/mL [P < .01]). Among patients treated with infliximab with therapeutic drug levels, we observed no difference in treatment failure between participants assigned monotherapy or combination therapy. Among patients treated with adalimumab, a trend towards reduced treatment failure in the combination therapy arm was not statistically significant (P = .14).
Conclusions
LD-MTX combination was not associated with higher drug levels, but higher drug levels were associated with reduced risk of treatment failure. Among patients with therapeutic drug levels, we observed no benefit of LD-MTX for patients treated with infliximab. A nonsignificant trend towards reduced treatment failure with the addition of LD-MTX patients treated with adalimumab warrants further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Stanford Medicine Children's Health, Palo Alto, CA, USA.
- Division of Gastroenterology, Hepatology, and Nutrition, C.S. Mott's Children's Hospital, Ann Arbor, MI, USA.
- Susan B. Meister Child Health Evaluation and Research Center, University of Michigan, Ann Arbor, MI, USA.
- Department of Medical Affairs, Dayton Children's Hospital and Wright State University, Dayton, OH, USA.
- Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
- Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Children's Hospital of The King's Daughters, Norfolk, VA, USA.
ORCID-Profile: Jonathan Moses, Anastasia Ivanova, Phillip Minar
Förderung
- Patient Centered Outcomes Research Institute
- Helmsley Charitable Trust
- Progenika Biopharma
- Esoterix Specialty Laboratory
- Labcorp
Zitieren
APA
Moses, J., Adler, J., Saeed, S. A., Firestine, A. M., Galanko, J. A., Ammoury, R. F., Bass, D. M., Bass, J. A., Bastidas, M., Benkov, K. J., Bousvaros, A., Cabrera, J. M., Chun, K. Y., Dorsey, J. M., Ebach, D. R., Gulati, A. S., Herfarth, H. H., Ivanova, A., Jester, T. W., …, & Kappelman, M. D. (2025). Low Anti-Tumor Necrosis Factor Levels During Maintenance Phase Are Associated With Treatment Failure in Children With Crohn’s Disease. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izae239
Vancouver
Moses J, Adler J, Saeed SA, Firestine AM, Galanko JA, Ammoury RF, et al. Low Anti-Tumor Necrosis Factor Levels During Maintenance Phase Are Associated With Treatment Failure in Children With Crohn’s Disease. Inflammatory Bowel Diseases. 2025. doi:10.1093/ibd/izae239
BibTeX
@article{Moses2025,
author = {Moses, Jonathan and Adler, Jeremy and Saeed, Shehzad A and Firestine, Ann M and Galanko, Joseph A and Ammoury, Rana F and Bass, Dorsey M and Bass, Julie A and Bastidas, Monique and Benkov, Keith J and Bousvaros, Athos and Cabrera, José M and Chun, Kelly Y and Dorsey, Jill M and Ebach, Dawn R and Gulati, Ajay S and Herfarth, Hans H and Ivanova, Anastasia and Jester, Traci W and Kaplan, Jess L and Kusek, Mark E and Leibowitz, Ian H and Linville, Tiffany M and Margolis, Peter A and Minar, Phillip and Molle-Rios, Zarela and Niklinska-Schirtz, Barbara Joanna and Olano, Kelly K and Osaba, Lourdes and Palomo, Pablo J and Pashankar, Dinesh S and Pitch, Lisa and Samson, Charles M and Sandberg, Kelly C and Steiner, Steven J and Strople, Jennifer A and Sullivan, Jillian S and Tung, Jeanne and Wali, Prateek and Wohl, David A and Zikry, Mike and Boyle, Brendan M and Kappelman, Michael D},
title = {Low Anti-Tumor Necrosis Factor Levels During Maintenance Phase Are Associated With Treatment Failure in Children With Crohn’s Disease},
journal = {Inflammatory Bowel Diseases},
year = {2025},
doi = {10.1093/ibd/izae239}
}
EUVIMED